Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis [0.03%]
Huntingtons病舞蹈症状的氘化四苯甲酰胺治疗效果：一个双点位分析 在美国食品药品监督管理局最大批准剂量以上剂量的治疗效果分析
Kayla Dodson,Sabrina Livezey,Brittany Denson et al.
Kayla Dodson et al.
BackgroundDeutetrabenazine, a vesicular monoamine transporter 2 inhibitor, is one of few treatment options available for Huntington's disease (HD) chorea. There is limited data describing clinical experience with deutetrabenazine doses >48 ...
Comparative analysis of neurofilament light chain in Huntington's disease like 2 and Huntington's disease [0.03%]
亨廷顿舞蹈病样2型和亨廷顿舞蹈病的神经丝轻链比较分析
David G Anderson,Aline Ferreira-Correia,Filipe B Rodrigues et al.
David G Anderson et al.
Huntington's disease-like 2 (HDL2) closely resembles Huntington's disease (HD) in clinical and pathological features. Neurofilament light chain (NfL) is an important biomarker in HD research and holds potential in HDL2. To evaluate NfL's ut...
Andrew M Tan,Michal Geva,Y Paul Goldberg et al.
Andrew M Tan et al.
Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor, cognitive, and behavioral impairments. Antidopaminergic medications (ADMs), such as VMAT2 inhibitors and antipsychotics, are commonly used to manage HD m...
Through their eyes: A retrospective mixed-methods study on the experiences and support needs of children growing up with a parent with Huntington's disease [0.03%]
通过他们的双眼：一项对成长过程中父母患有亨廷顿舞蹈病的儿童的经历和需求的回顾性混合方法研究
Maud Mj Daemen,Annelien A Duits,Lucienne B van der Meer et al.
Maud Mj Daemen et al.
Background: Growing up with a parent with Huntington's disease (HD) profoundly impacts children. However, this impact and children's needs are often misunderstood, even by professional services. Even when resources are av...
Absence of hippocampal pathology persists in the Q175DN mouse model of Huntington's disease despite elevated HTT aggregation [0.03%]
尽管HTT聚集增加，Q175DN亨廷顿舞蹈病小鼠模型中海马病理学的缺失仍然存在
Melissa A Solem,Ross G Pelzel,Nicholas B Rozema et al.
Melissa A Solem et al.
Background: Huntington's disease (HD) is a neurodegenerative disorder causing motor, cognitive, and psychiatric impairments, with the striatum being the most affected brain region. However, the role of other regions, such...
Frequency of depression in Huntington's disease: A systematic review and meta-analysis [0.03%]
亨廷顿病抑郁症的发病率：系统回顾和荟萃分析
Shayan Abdollah Zadegan,Frank Ramirez,Jung Woo Park et al.
Shayan Abdollah Zadegan et al.
Background: Huntington's disease (HD) is a hereditary neurodegenerative disease characterized by a combination of motor, cognitive, and mental health issues, with depression being the most common. Despite its importance, ...
Pooja Gokhale,Lorenzo Villa Zapata
Pooja Gokhale
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease, characterized by progressive motor, cognitive, and psychiatric symptoms. The disease poses a significant social and economic burden...
Anxiety, memory, and social impairments in the YAC128 mouse model of Huntington's disease [0.03%]
亨廷顿舞蹈病YAC128小鼠模型中的焦虑，记忆和社交障碍
Ksenia S Marinina,Ilya B Bezprozvanny,Polina A Egorova
Ksenia S Marinina
Background: Huntington's disease (HD) is an autosomal dominant hereditary disorder, caused by an expansion of polyglutamine in the huntingtin protein. HD is characterized by a progressive decline in motor functions. This ...
Mortality trends and disparities in adults with Huntington's disease in the United States [0.03%]
美国亨廷顿氏病成人患者的死亡率趋势和差异分析
Humza Saeed,Abdullah,Hira Hameed et al.
Humza Saeed et al.
Background: Huntington's disease (HD), an autosomal dominant disorder, is characterized by progressive neurodegeneration, psychiatric issues, dementia, and worsening chorea over time. Its prevalence varies by ethnicity an...